APG-115 (MDM2-p53 inhibitor)
GPTKB entity
Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
small molecule
investigational drug |
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
gptkb:Ascentage_Pharma
|
| https://www.w3.org/2000/01/rdf-schema#label |
APG-115 (MDM2-p53 inhibitor)
|
| gptkbp:indication |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
inhibits MDM2-p53 interaction
|
| gptkbp:restored |
p53 tumor suppressor activity
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
APG-115
|
| gptkbp:target |
gptkb:MDM2
|
| gptkbp:bfsParent |
gptkb:Ascentage_Pharma
|
| gptkbp:bfsLayer |
7
|